Lucia Masarova/X
Sep 5, 2025, 12:18
Lucia Masarova Presents Results of Phase III SURPASS-ET Trial at SOHO 2025: Ropeg’s Efficacy for Essential Thrombocythemia
MPN Hub shared on X:
”CONGRESS | SOHO 2025 | POSTER
Lucia Masarova, MD Anderson Cancer Center
Presents results from the phase III SURPASS-ET trial of ropeginterferon alfa-2b (n=91) vs anagrelide (n=83) in patients with HR Essential Thrombocythemia who are resistant or intolerant to hydroxyurea.
Ropeg showed superior efficacy over anagrelide (RR, 42.9% vs 6.0%, P=0.0001) and demonstrated a favorable safety profile.”
All on Hemostasis and Thrombosis from SOHO 2025 featured in Hemostasis Today.
-
Aug 6, 2026, 07:20Mohammed Anas: Vitamin B12 Is Something You Cannot Afford to Ignore
-
Aug 6, 2026, 07:09Domenico Girelli: Why Hemoglobin Alone Is Not Enough Before Surgery
-
Aug 6, 2026, 06:58Rob Mac Sweeney: Traumatic DIC – A Modern Review
-
Aug 6, 2026, 06:49Mukhyaprana Prabhu: Advancing Precision Biomarkers in Systemic Lupus Erythematosus
-
Aug 6, 2026, 05:53Gender-Affirming Hormone Therapy and Thrombosis – RPTH Journal
-
Aug 6, 2026, 04:58Shamee Shastry: Advancing Precision in Massive Bleed Management
-
Aug 6, 2026, 01:21Orly Leiva: High-Output Heart Failure Signals Disease Progression in PV and ET
-
Aug 5, 2026, 23:46Recommended ESC Congress Sessions for the ESC Working Group on Thrombosis
-
Aug 5, 2026, 23:36Heghine Khachatryan: ISTH Day 2 – Phase III VAYHIT2 Data Highlights Ianalumab in Primary ITP